ALK and non-small cell lung carcinoma: Alectinib, one of these inhibitors, has gained prominence due to its long-term efficacy, high selectivity, and central nervous system (CNS) active ALK-inhibiting activity.[11] It is important to note that alectinib is not the only drug in this category; other options include brigatinib, crizotinib, ceritinib, and various other drugs.[12] Meanwhile, patients with other NSCLC subtypes may require different therapies based on their specific genetic profiles.